Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsTABLETGeneric

LASMIDITAN

LASMIDITAN

Standard Dose
50MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview LASMIDITAN is listed in Drugs@FDA under application 219350 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient LASMIDITAN Form and strength TABLET - 50MG Sponsor QILU PHARMACEUTICAL CO., LTD.

Structured Monograph

Clinical summary

Approval overview LASMIDITAN is listed in Drugs@FDA under application 219350 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient LASMIDITAN Form and strength TABLET - 50MG Sponsor QILU PHARMACEUTICAL CO., LTD. Submission history Latest submission status date: 2024-12-20 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.